Kornimate/medical-research-clean huggingface dataset:
the carewell-programme for community-dwelling frail elderly persons.

Conditions: Overall Functioning; Incremental Cost-effectiveness Ratio

Summary: the purpose of this study is to investigate the effect of the carewell-programme on overall functioning of community-dwelling frail elderly persons. furthermore, the total costs and the cost-effectiveness of the carewell-programme, in comparison with regular medical care, will be studied.


Eligibility criteria:
inclusion criteria: * frail community dwelling elderly patients aged 70 years or above. frailty is determined with a two-phase screening instrument. exclusion criteria: * non-frail elders * patients in palliative or end-of-life stages of disease * patients residing in long-term care facilities (care homes and nursing homes) * patients already enrolled in specific dementia-related case-management programmes who lack other health-related problems * patients not speaking or understanding the dutch language

Keywords: frailty frail elders multicomponent intervention overall functioning cost-effectiveness integrated care primary care community dwelling
progressive resistance strength training (prt) in hospitalised elderly patients

Conditions: Medical Diseases; Neurological Diseases; Chronical Obstructive Lung Diseases

Summary: the aim of the study is to evaluate the effect of progressive resistance strength training (prt) in elderly hospitalised patients. the hypothesis is that prt given as an additional training would improve the rehabilitation and increase the level of activity of daily living.

elderly inpatients included in the study were randomised into a control group or a training group. all included patients received the regular in-physiotherapy, but the training group received progressive resistance training in groups in addition.

Eligibility criteria:
inclusion criteria: 1. hospitalised elderly patients referred for physiotherapy. 2. ability to perform standing position independently with/without walking aids (rollator, crutch) or bed/bench support. exclusion criteria: 1. expected length of stay \< 7 days. 2. dementia. 3. unable to communicate relevant. 4. unable to be active

Keywords: barthel index elderly hospitalised patients progressive resistance training
virtual specialty clinic for fibromyalgia care

Conditions: Fibromyalgia

Summary: this is an ongoing, prospective, and retrospective cohort study of fibromyalgia patients who receive clinical care at swing care (a fibromyalgia virtual specialty clinic). deidentified data on demographics, clinical outcomes, patients' treatment engagement and preference, as well as patients' satisfaction are obtained and analyzed via retrospective and prospective chart review. a waiver of informed consent has been approved by the reviewing institutional review board.


Eligibility criteria:
inclusion criteria: * adult patients of swing care between 1 oct, 2022 and 1 oct, 2027, who received clinical evaluations and/or treatments according to swing care's standard clinical care protocol. exclusion criteria: none
efficacy of valsartan/hydrochlorothiazide versus amlodipine and hydrochlorothiazide in patients hypertension

Conditions: Hypertension

Summary: this study will evaluate the efficacy of valsartan/hydrochlorothiazide versus amlodipine and hydrochlorothiazide in patients with stage 2 hypertension using 24-hr ambulatory blood pressure monitoring (abpm)


Eligibility criteria:
inclusion criteria: * male or female patients 18 years of age or older * diagnosed of having hypertension, defined as a mean seated systolic bp ≥160 mmhg (stage 2 hypertension) exclusion criteria: * symptomatic or severe hypertension * patients treated with more than 2 antihypertensive medications * clinically known or suspected history of secondary hypertension * myocardial infarction, stroke, transient ischemic attack, cardiovascular revascularization/angioplasty in last 6 months * diagnosis of heart failure (nyha class ii-iv) * chronic renal or severe hepatic disease

Keywords: hypertension, valsartan/hctz, amlodipine and hctz
a phase iii study to evaluate the efficacy and safety of ak111 in subjects with active ankylosing spondylitis

Conditions: Ankylosing Spondylitis

Summary: this is a randomized, double-blind, placebo-controlled, multi-center phase iii clinical study to evaluate the efficacy and safety of ak111 in the treatment of subjects with active ankylosing spondylitis.

the study consists of 3 parts. part 1 is screening period, part 2 is placebo control period and part 3 is long term treatment follow-up period. the research period is 61 weeks in total.

Eligibility criteria:
inclusion criteria: * male or female subjects aged ≥18 years old. * subjects with confirmed ankylosing spondylitis before screening. * during screening and before randomization, basdai score ≥ 4, total back pain score≥ 4. * subjects received at least 2 kind of non-steroidal anti-inflammatory drugs (nsaids), prior to randomization with an inadequate response or failure to respond, or with contraindications or intolerance to the use of nsaids. * subjects who are regularly taking nsaids, weak opioids or oral glucocorticoids(the daily dose should be ≤10mg prednisone or equivalent dose of glucocorticoid) as part of their as therapy are required to be on a stable dose for at least 14 days before randomization. if the drug has been discontinued, at least 2 weeks washout period is required before randomization. * subjects taking methotrexate (mtx) (≤25mg/week) or sulfasalazine (≤3g/day) are allowed to continue their medication if started at least 12 weeks prior to baseline, with a stable dose for at least 4 weeks before randomization. if the drug has been discontinued, at least 4 weeks washout period is required before randomization. * subjects who are able to understand and voluntarily sign the icf and complete the study procedure. exclusion criteria: * subjects with symptom of pain that affected the evaluation of efficacy. * subjects with other inflammatory diseases or autoimmune diseases except ankylosing spondylitis (as). * subjects who are using strong opioid analgesics. * received glucocorticoid intramuscular or intravenous injection within 2 weeks prior to randomization; received intraarticular or paraspinal glucocorticoid therapy within 4 weeks before randomization. * received other antirheumatic drugs (except methotrexate, sulfasalazine), proprietary chinese medicine or traditional chinese medicine decoction, jak inhibitor treatment for as within 4 weeks before randomization. * received natalizumab or other b cell or t cell modulator in the 12 months prior to randomization. * previous exposure to secukinumab, ixekizumab or any other biologic drug directly targeting il-17 or il-17 receptor. * received multiple tumor necrosis factor α (tnf-α) inhibitors; the eluting period of biologics received before randomization is shorter than the protocol. * participated in a clinical study of any other drug or medical device within 1 month (≤30 days) prior to randomization, or last received the investigational drug within 5 half-lives. * the presence of any other systemic disease or laboratory abnormalities that the investigator has judged unsuitable for clinical trials.
raspberry ketone intake upregulates circulating fgf21 and induces energy expenditure in humans

Conditions: Obesity; Diabetes; NAFLD (Nonalcoholic Fatty Liver Disease)

Summary: to investigate the molecular mechanism of raspberry ketone on regulating obesity, the investigators studied the effect of raspberry ketone intake on fgf21 in plasma. the age of the volunteers were 18-60 years old, both male and female, without diabetes, hypertension and other diseases. after ingestion of raspberry ketone (500mg), 2ml of blood was collected at 0 hours, 3 hours and 6 hours , and the fgf21 content in plasma was measured using a commercial reagent kit. in addition, the investigators also studied the effect of raspberry ketone intake on energy metabolism 0 hours, 0.5 hours, 3 hours and 6 hours after consuming raspberry ketone (500mg).


Eligibility criteria:
inclusion criteria: no drugs were taken before the human study exclusion criteria: patients with hypertension
approaches for open reduction and internal fixation of mandibular condylar fracture

Conditions: Mandibular Fractures

Summary: the condylar region is the most frequent anatomical site for mandibular fractures . condylar fractures constitute 25.5% to 35.5% of all mandibular fractures. the mandibular condyle fracture is a type of fracture that affects the condyle, which is the knuckle-like projection of the mandible (lower jaw) that articulates with the temporal bone to form the temporomandibular joint (tmj).

several approaches have been used for condylar fracture including intraoral, preauricular, submandibular and retromandibular approaches. the selection of the appropriate surgical approach for condylar neck fracture represents a controversy. the purpose of this study is to compare the outcomes and effectiveness between the retromandibular transparotid approach and retromandibular retroparotid approach for treatment of condylar fracture of mandible.

Eligibility criteria:
inclusion criteria: * all patients diagnosed with extra capsular fracture of mandibular condyle amenable for surgery. exclusion criteria: * 1. open laceration in the condylar region. 2. concomitant traumatic facial nerve injury. 3. previous surgery in retromandibular region. 4. severe obese patients 5. patients refusing surgery.

Keywords: mandibular condylar fracture approaches for mandibular fractures transparotid retromandibular comparative study retroparotid
efficacy of robot-assisted technique vs conventional technique in preventing early micromobilisation after uka

Conditions: Loosening, Prosthesis

Summary: the purpose of this study is to compare the percentage of early micromibilisation in unicompartmental knee arthroplasties in robot-assisted technique vs standard technique.

the purpose of the study is to compare the percentage of early micromobilisation by static radiostereometric analysis (rsa) - primary outcome, gait analysis by inertial sensors to assess gait kinematics, and clinical perdormance measured by american knee society score (akss), oxford knee score (oks), patient satisfaction score (pss) and eq5-d - secondary outcomes, among 2 groups of patients, of 25 individuals each, whi undergo medial unicompartmental knee arthroplasty. the first group will be operated with a robot-assisted technique (with cori surgical system, smith and nephew, usa), the other with standard technique and the same implant (journey uni ii, smith and nephew, usa). the study will be a randomized and controlled blind superiority trial. patients will not be informed about performing the surgery with one technique or the other in order to avoid potential biases in the data analysis. patients will be recruited at the orthoaedic and traumatologic 2nd clinica (head prof s. zaffagnini) at ircss istituto ortopedico rizzoli in bologna, italy.

Eligibility criteria:
inclusion criteria: * unicompartmental knee arthrosis * femoral condyles or medial tibial plate osteonecrosis * healthy anterior cruciate ligament, posterior cruciate ligament and collateral ligaments of the affected knee * post traumatic loss of joint configuration * moderate varism deformity * patients between 50 and 80 years old * patients able to undergo a 2-year follow up after surgery exclusion criteria: * bi or tricompartmental arthrosis * unhealty anterior or posterior cruciate ligaments or collateral ligaments * patients with neuromuscolar, degenerative and joint-related conditions * patients younger than 50 * patients older than 80 * patients unable to undergo a 2-year follow up after surgery
monitoring of covid-19 seroprevalence among ghdc staff members

Conditions: Covid19

Summary: grand hôpital de charleroi (ghdc) had to organize the vaccination of its staff in december 2021 against sars-cov-2.on the sidelines of this vaccination campaign, the management committee agreed to document the knowledge of the sars-cov-2 serology of all the staff of the establishment before this vaccination campaign, as well as a few weeks after vaccination. in november 2021, the belgian government decided to offer a third dose of vaccine against sars-cov-2 virus. the ghdc managment committee has agreed to continue monitoring sars-cov-2 serology for members who receive their third dose of vaccine.

grand hôpital de charleroi (ghdc) staff were exposed to the risk of sars-cov-2 infection during the first half of 2020: a seroprevalence survey, conducted in the summer of 2020, after the "first wave" of the epidemic, and before the "second wave", thus revealed a significant seroprevalence because of its exposure. this study, because of its high participation rate, also showed the sustained interest of the agents in knowing their serology, either for personal reasons, or for the purposes of recognition as an occupational disease. the ghdc decided in december 2020 to organize as soon as possible the vaccination of its salaried and self-employed employees who wish to take advantage of this opportunity. on the sidelines of this vaccination campaign, the management committee agreed to document the knowledge of the sars-cov-2 serology of all the staff of the establishment before this vaccination campaign, as well as a few weeks after vaccination. this knowledge must better organize the disease prevention strategy, both with regard to the staff themselves and the patients for whom they are called upon to treat. when the belgian government decided in november 2021 to offer a third dose of vaccine and start it up in hospitals, the ghdc managment committee has agreed to continue monitoring sars-cov-2 serology for members who agree to receive their third dose of vaccine.

Eligibility criteria:
inclusion criteria: * to be an employee or independent collaborator at the ghdc exclusion criteria: * refusal to take a blood test for anti-sars-cov-2 antibodies regarding amendment 1: * members who did not receive the third dose of pfizer vaccine (comirnaty) during the ghdc vaccination campaign and who did not performed a blood test to measure anti-sars-cov-2 antibodies.
impact of non-surgical periodontal therapy in the improvement of early endothelial dysfunction in subjects with periodontitis.

Conditions: Atherosclerosis; Periodontitis

Summary: a double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with periodontitis and without any cardiovascular disease.

a double-blind randomized-controlled clinical trial is conducted in order to evaluate the impact of non-surgical periodontal treatment on endothelial dysfunction parameters in subjects with periodontitis and without any cardiovascular disease. 60 patients: 30 with periodontitis and 30 with healthy controls and without periodontitis history. all the patients are assessed for clinical, periodontal, blood and non-invasive ultrasound cardiovascular parameters. measurements are taken before and after initial periodontal treatment in the periodontal subjects.

Eligibility criteria:
periodontitis group inclusion criteria: * clinically diagnosed with periodontitis according to the efp/aap 2017 criteria. exclusion criteria: * periodontal treatment, antibiotics, nsaids, immunosuppressants during the last 6 months. * pregnancy. * cardiovascular diseases. healthy group inclusion criteria: * clinically diagnosed with healthy periodontum withouth periodontitis history according to the efp/aap 2017 criteria. exclusion criteria: * scaling, antibiotics, nsaids, immunosuppressants during the last 6 months. * pregnancy. * cardiovascular diseases.
validation of dna methylation biomarkers for oral cancer detection

Conditions: Oral Cancer

Summary: the aim of this study is to evaluate the association between several methylated genes and oral cancers. a prospective case control trial is designed with sample size estimated at least 160 cases. it is expected to enroll at least 100 subjects with precancerous lesion or oral cancer, and \~60 subjects with normal oral mucosa. this study is approved by the national taiwan university hospital research ethics committee. after signing the informed consent, all of the subjects will receive an intraoral examination and the oral epithelial cells will be collected. if abnormal oral lesion is observed, it will be photographed, and the biopsy will be performed to confirm the diagnosis. for methylated gene detections, the gdna will be extracted from the collected cells and standardized assay will be performed. clinical sensitivity and specificity for these methylated genes will be evaluated.


Eligibility criteria:
inclusion criteria: * subject with age over 20. * subject agrees to sign the informed consent form. exclusion criteria: * subjects have history of head and neck cancer. * subjects have had received chemotherapy for cancers. * pregnant woman * subjects whose has oral mucosal lichen planus. * subjects whose oral mucosal findings is abnormal, but the diagnosis is unknown.

Keywords: dna methylation, biomarkers, oral cancer
observational study to evaluate the time to achieving the maintenance dose of zemplar® (paricalcitol injection) in the treatment of patients suffering from end-stage renal disease and severe over-reactivity of the parathyroid glands

Conditions: Kidney Failure, Chronic

Summary: this observational study will evaluate the clinical benefit of zemplar (paricalcitol injection) in daily routine practice in end-stage renal disease patients with severe over-reactivity of parathyroid glands. participants will be followed for 6 months. data will be collected from participants initiated on zemplar therapy according to standard of care. the time to achieving the maintenance dose of zemplar (paricalcitol injection), the proportion of participants achieving target parathyroid hormone levels, and prevalence of elevated serum calcium and phosphate levels will be evaluated.

prospective data collection started at initial dosing with zemplar (paricalcitol injection) and ended up to 6 months later. if available, retrospective data on vitamin d treatment as well as on the incidence of hypercalcaemia and hyperphosphataemia in the 6 months leading up to paricalcitol treatment were also collected. eight visits were planned for documentation of prospective data. in accordance with the non-interventional character of the study, only diagnostic and monitoring procedures were applied which are part of the routine medical care of secondary hyperparathyroidism.

Eligibility criteria:
inclusion criteria: based on the current hungarian summary of product characteristics for zemplar (paricalcitol injection), the patient is entitled to treatment with paricalcitol injection and: 1. ≥ 18 years of age, 2. willing to sign the patient information and informed consent form, 3. chronic kidney disease (ckd) stage 5 patient receiving haemodialysis with a diagnosis of secondary hyperparathyroidism (shpt), whose intact parathyroid hormone (ipth) level is: * between 500-800 pg/ml with at least two abruption of conventional vitamin d therapy due to elevated serum calcium level (i.e. \> 2.4 mmol/l) in the medical history, or * higher than 800 pg/ml and parathyroidectomy is contraindicated. 4. the patient is planned to receive paricalcitol treatment independently from his/her participation in this study. exclusion criteria: patients cannot be enrolled in the study if any of the following exclusion criteria apply: 1. the patient is already treated with zemplar (paricalcitol injection), 2. any contraindication exists as stated in the current hungarian summary of product characteristics for zemplar (paricalcitol injection), 3. patients who decline to participate in the study or decline to sign the patient information/informed consent form.

Keywords: parathyroid hormone,kidney failure, chronic,hyperparathyroidism, secondary
exenatide once weekly for smoking cessation

Conditions: Smoking Cessation

Summary: the purpose of this study is to identify a potential new treatment for smoking cessation.


Eligibility criteria:
inclusion criteria: * be english-speaking volunteers who desire to quit smoking and are willing to make a quit attempt during the course of the study; * have smoked ≥10 cigarettes a day for at least one year and provide a breath carbon monoxide (co) ≥10 ppm; * have a negative pregnancy test, if female of childbearing potential; * have hba1c levels between 5.7 and 6.4% or bmi of or greater than 25 kg/square meters * not currently using any therapy for glycemic control (either injectable \[i.e. insulin\] or oral agents); * have vital signs as follows: resting pulse between 50 and 95 bpm, bp between 90-150 mmhg systolic and 45-95 mmhg diastolic; * have hematology and chemistry laboratory tests that are within reference limits (within 10% above or below), with the following exception: pancreatic tests (lipase and amylase) must be within normal limits; * have a medical history and brief physical examination demonstrating no clinically significant contraindications for study participation, in the judgment of the principal investigator. exclusion criteria: * meet criteria for the following psychiatric and/or substance use disorders as assessed by the mini international neuropsychiatric interview (mini): items c (current manic or hypomanic episode only), i (alcohol abuse - alcohol addendum-past 3 months only; current alcohol dependence), j (substance abuse -substance abuse addendum - past 3 months only; current substance dependence), k (current psychotic disorder or current mood disorder with psychotic features). * individuals who meet criteria for non-exclusionary psychiatric disorders that are considered clinically unstable and/or unsuitable to participate as determined by the principal investigator and/or study physician. * individuals rated as moderate (9-16) to high (17 or greater) on suicidality as assessed by module b of the mini. * have personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2; * have type 1 diabetes mellitus; * have severe cardiovascular disease (history of myocardial infarction, life-threatening arrhythmia, or worsening angina pectoris); * have active temporomandibular joint disease; * have severe gastrointestinal disease (i.e. severe gastroparesis); * have previous history of pancreatitis or are at risk for pancreatitis; * have creatinine clearance (crcl) \< 30; * have any previous medically adverse reaction to study medications, nicotine, or menthol; * be pregnant or lactating or unwilling to provide a negative pregnancy test before study entry; * not using a reliable form of contraception (e.g., abstinence, birth control pills, intrauterine device, condoms, or spermicide); * have any illness which in the opinion of the primary investigator would preclude safe and/or successful completion of the study.

Keywords: smoking pre-diabetes overweight exenatide glucagon-like peptide-1 (glp-1) agonists